Arrowhead Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ARWR)

$5.80 +0.26 (+4.69 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$5.80
Today's Range$5.35 - $5.81
52-Week Range$1.42 - $6.75
Volume955,331 shs
Average Volume1.95 million shs
Market Capitalization$526.99 million
P/E Ratio-12.34
Dividend YieldN/A
Beta2.52

About Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ARWR
CUSIPN/A
Phone+1-626-3043400

Debt

Debt-to-Equity Ratio0.03%
Current Ratio3.87%
Quick Ratio3.87%

Price-To-Earnings

Trailing P/E Ratio-12.3404255319149
Forward P/E Ratio-8.79
P/E GrowthN/A

Sales & Book Value

Annual Sales$31.41 million
Price / Sales16.03
Cash FlowN/A
Price / CashN/A
Book Value$0.81 per share
Price / Book7.16

Profitability

Trailing EPS($0.47)
Net Income$-34,380,000.00
Net Margins-116.17%
Return on Equity-42.52%
Return on Assets-32.70%

Miscellaneous

Employees93
Outstanding Shares86,790,000

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced its quarterly earnings results on Tuesday, December, 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.02. The biotechnology company had revenue of $8.71 million for the quarter, compared to analysts' expectations of $7.32 million. Arrowhead Pharmaceuticals had a negative net margin of 116.17% and a negative return on equity of 42.52%. View Arrowhead Pharmaceuticals' Earnings History.

When will Arrowhead Pharmaceuticals make its next earnings announcement?

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Arrowhead Pharmaceuticals.

Where is Arrowhead Pharmaceuticals' stock going? Where will Arrowhead Pharmaceuticals' stock price be in 2018?

6 brokerages have issued 1-year price targets for Arrowhead Pharmaceuticals' shares. Their forecasts range from $2.00 to $7.00. On average, they expect Arrowhead Pharmaceuticals' share price to reach $4.70 in the next twelve months. View Analyst Ratings for Arrowhead Pharmaceuticals.

What are Wall Street analysts saying about Arrowhead Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arrowhead Pharmaceuticals stock:

  • 1. Chardan Capital analysts commented, "We believe that Arrowhead is positioned to achieve a number of significant milestones in 2018. The Company spent most of 2017 quietly regrouping following its announcement in November 2016 that it was discontinuing all of its clinical RNAi programs (ARC-520, ARC-521, and ARC-AAT), which use its dynamic polyconjugate (DPC) delivery technology. The decision to discontinue development of these programs was based on the substantial delays that would have occurred in order to further explore the cause of deaths in a non-clinical toxicology study in non-human primates. Arrowhead subsequently reduced its workforce by approximately 30%. In September 2017, the Company unveiled its new proprietary delivery technology they call Targeted RNAi Molecule (TRiM), along with a portfolio of newly named candidates. Arrowhead’s TRiM delivery technology leverages advances in RNA chemistry and targeting, to deliver a payload with increased potency." (2/19/2018)
  • 2. Cantor Fitzgerald analysts commented, "Arrowhead reiterated its recently disclosed timeline for returning to clinical development with at least two indications (AAT and HBV) in 1H18." (9/25/2017)

Are investors shorting Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals saw a increase in short interest during the month of January. As of January 12th, there was short interest totalling 4,478,905 shares, an increase of 51.3% from the December 29th total of 2,959,910 shares. Based on an average trading volume of 3,400,352 shares, the short-interest ratio is presently 1.3 days. Approximately 7.0% of the shares of the company are sold short.

Who are some of Arrowhead Pharmaceuticals' key competitors?

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the folowing people:

  • Douglass B. Given M.D., Ph.D., Chairman of the Board (Age 64)
  • Christopher Richard Anzalone Ph.D., President, Chief Executive Officer, Director (Age 47)
  • Kenneth Allen Myszkowski, Chief Financial Officer (Age 50)
  • Bruce D. Given M.D., Chief Operating Officer (Age 62)
  • Patrick O'Brien, General Counsel (Age 53)
  • Michael S. Perry Ph.D., Lead Independent Director (Age 57)
  • Mauro Ferrari Ph.D., Independent Director (Age 57)
  • Edward W. Frykman, Independent Director (Age 80)
  • William D. Waddill, Independent Director (Age 60)

Who owns Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include OppenheimerFunds Inc. (7.26%), NOVARTIS AG (4.44%), NOVARTIS AG (4.44%), First Manhattan Co. (4.25%), SILENCE THERAPEUTICS PLC (3.70%) and BlackRock Inc. (3.17%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Douglas B Given and Kenneth Allen Myszkowski. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

Who sold Arrowhead Pharmaceuticals stock? Who is selling Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including ING Groep NV, Millennium Management LLC, BlackRock Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Who bought Arrowhead Pharmaceuticals stock? Who is buying Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., First Manhattan Co., Goldman Sachs Group Inc., Alps Advisors Inc., BlueCrest Capital Management Ltd, Acadian Asset Management LLC, Quantitative Investment Management LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

How do I buy Arrowhead Pharmaceuticals stock?

Shares of Arrowhead Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of Arrowhead Pharmaceuticals stock can currently be purchased for approximately $5.80.

How big of a company is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has a market capitalization of $526.99 million and generates $31.41 million in revenue each year. The biotechnology company earns $-34,380,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Arrowhead Pharmaceuticals employs 93 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 225 S Lake Ave Ste 1050, PASADENA, CA 91101-4820, United States. The biotechnology company can be reached via phone at +1-626-3043400 or via email at [email protected]


MarketBeat Community Rating for Arrowhead Pharmaceuticals (ARWR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  330
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldHoldHold
Consensus Rating Score: 2.502.332.202.00
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.70$3.13$2.00$1.80
Price Target Upside: 15.62% downside50.32% downside43.66% downside2.17% downside

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Consensus Price Target History

Price Target History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/19/2018Chardan CapitalReiterated RatingBuy$7.00LowView Rating Details
2/12/2018B. RileyBoost Price TargetNeutral -> Neutral$3.00 -> $4.00MediumView Rating Details
2/12/2018Cantor FitzgeraldSet Price TargetNeutral -> Neutral$2.00 -> $5.00MediumView Rating Details
11/27/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$5.50HighView Rating Details
9/18/2017William BlairUpgradeMarket Perform -> OutperformHighView Rating Details
8/4/2017Jefferies GroupReiterated RatingHold$2.00HighView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings History and Estimates Chart

Earnings by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ ARWR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018N/AView Earnings Details
2/9/2018Q1 2018($0.14)($0.18)$8.71 million$3.51 millionViewListenView Earnings Details
12/12/2017Q4 2017($0.12)($0.14)$7.32 million$8.71 millionViewN/AView Earnings Details
8/3/2017Q3 2017($0.13)($0.07)$5.29 million$9.34 millionViewListenView Earnings Details
5/3/2017Q2 2017($0.12)($0.08)$4.19 million$8.99 millionViewListenView Earnings Details
2/6/2017Q117($0.20)($0.17)$13.24 million$4.37 millionViewListenView Earnings Details
12/14/2016Q4 2016($0.33)($0.31)$0.04 million$0.03 millionViewN/AView Earnings Details
8/9/2016Q316($0.37)($0.32)$0.05 million$39.58 millionViewN/AView Earnings Details
5/10/2016Q216($0.37)($0.35)$0.26 million$0.04 millionViewListenView Earnings Details
2/9/2016Q1($0.41)($0.32)$0.29 million$0.04 millionViewN/AView Earnings Details
12/14/2015Q415($0.39)($0.42)$0.14 million$0.04 millionViewListenView Earnings Details
8/4/2015Q315($0.38)($0.27)$0.11 million$0.12 millionViewN/AView Earnings Details
5/11/2015Q214($0.35)($0.33)$110.00 million$43.75 millionViewListenView Earnings Details
2/9/2015Q114($0.32)($0.41)$0.24 million$0.17 millionViewN/AView Earnings Details
11/25/2014Q413($0.25)($0.33)$0.04 million$0.04 millionViewN/AView Earnings Details
8/12/2014Q313($0.22)($0.22)$0.04 million$0.04 millionViewN/AView Earnings Details
5/6/2014Q2 2014($0.18)($0.31)$0.05 million$0.04 millionViewN/AView Earnings Details
2/4/2014Q4($0.18)($0.33)$0.05 million$0.04 millionViewN/AView Earnings Details
12/18/2013Q4($0.23)($0.43)ViewListenView Earnings Details
8/7/2013Q3 2013($0.22)($0.23)$0.50 million$0.04 millionViewN/AView Earnings Details
5/9/2013Q2 2013($0.41)$0.04 millionViewN/AView Earnings Details
2/13/2013Q1 2013($0.33)ViewN/AView Earnings Details
12/20/2012Q4 2012($0.43)ViewN/AView Earnings Details
8/13/2012Q3 2012($0.71)ViewN/AView Earnings Details
5/8/2012Q2 2012($0.44)ViewN/AView Earnings Details
2/9/2012Q1 2012($0.25)ViewN/AView Earnings Details
12/20/2011Q4 2011($0.39)ViewN/AView Earnings Details
8/8/2011Q3 2011($0.20)($0.26)ViewN/AView Earnings Details
5/12/2011Q2 2011($0.20)($0.18)ViewN/AView Earnings Details
2/10/2011Q1 2011($0.20)ViewN/AView Earnings Details
12/22/2010Q4 2010($0.30)($0.28)ViewN/AView Earnings Details
8/12/2010Q3 2010($0.50)($0.06)ViewN/AView Earnings Details
5/13/2010Q2 2010($0.40)($0.33)ViewN/AView Earnings Details
2/11/2010Q1 2010($0.30)ViewN/AView Earnings Details
12/22/2009Q4 2009($0.60)ViewN/AView Earnings Details
8/10/2009Q3 2009($0.60)ViewN/AView Earnings Details
5/15/2009Q2 2009($1.20)ViewN/AView Earnings Details
2/9/2009Q1 2009($1.90)ViewN/AView Earnings Details
12/15/2008Q4 2008($2.14)ViewN/AView Earnings Details
8/11/2008Q3 2008($1.90)ViewN/AView Earnings Details
2/11/2008Q1 2008($1.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings Estimates

2018 EPS Consensus Estimate: ($0.68)
2019 EPS Consensus Estimate: ($0.94)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.13)($0.13)($0.13)
Q2 20182($0.20)($0.16)($0.18)
Q3 20182($0.20)($0.16)($0.18)
Q4 20182($0.21)($0.16)($0.19)
Q1 20191($0.22)($0.22)($0.22)
Q2 20191($0.23)($0.23)($0.23)
Q3 20191($0.24)($0.24)($0.24)
Q4 20191($0.25)($0.25)($0.25)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Arrowhead Pharmaceuticals (NASDAQ ARWR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 25.46%
Insider Trades by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Insider Trades by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ ARWR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/1/2018Bruce D GivenCOOSell20,000$3.69$73,800.00948,356View SEC Filing  
10/14/2016Douglas B. GivenDirectorSell12,000$6.72$80,640.00View SEC Filing  
8/23/2016Kenneth Allen MyszkowskiCFOSell6,900$8.00$55,200.00128,789View SEC Filing  
8/22/2016Kenneth Allen MyszkowskiCFOSell13,100$8.00$104,800.00128,789View SEC Filing  
12/30/2015Kenneth Allen MyszkowskiCFOSell23,347$6.13$143,117.11135,000View SEC Filing  
10/28/2015Mauro FerrariDirectorBuy400$7.62$3,048.00View SEC Filing  
10/9/2015Mauro FerrariDirectorBuy1,900$6.19$11,761.00View SEC Filing  
1/5/2015David L LewisInsiderSell15,000$8.01$120,150.00View SEC Filing  
10/15/2014Christopher Richard AnzaloneCEOBuy16,000$6.32$101,120.00View SEC Filing  
10/1/2014Charles MckenneyDirectorSell2,500$14.70$36,750.00View SEC Filing  
9/30/2014David L LewisInsiderSell15,000$15.02$225,300.00View SEC Filing  
9/26/2014Douglas B GivenDirectorSell2,000$15.24$30,480.00View SEC Filing  
6/9/2014Charles MckenneyDirectorSell22,000$14.32$315,040.00View SEC Filing  
2/12/2014Kenneth Allen MyszkowskiCFOSell16,000$18.77$300,320.00View SEC Filing  
2/7/2014Edward W FrykmanDirectorSell3,148$15.98$50,305.04View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Arrowhead Pharmaceuticals (NASDAQ ARWR) News Headlines

Source:
DateHeadline
Arrowhead Pharmaceuticals Corp (ARWR) Reports Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver DiseaseArrowhead Pharmaceuticals Corp (ARWR) Reports Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
www.streetinsider.com - February 23 at 8:52 AM
Contrasting Arrowhead Pharmaceuticals (ARWR) & Arcturus Therapeutics (ARCT)Contrasting Arrowhead Pharmaceuticals (ARWR) & Arcturus Therapeutics (ARCT)
www.americanbankingnews.com - February 22 at 5:20 PM
Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver DiseaseArrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
finance.yahoo.com - February 22 at 8:35 AM
Chardan Capital Reiterates "Buy" Rating for Arrowhead Pharmaceuticals (ARWR)Chardan Capital Reiterates "Buy" Rating for Arrowhead Pharmaceuticals (ARWR)
www.americanbankingnews.com - February 20 at 12:24 AM
Arrowhead Pharmaceuticals (ARWR) Downgraded by BidaskClubArrowhead Pharmaceuticals (ARWR) Downgraded by BidaskClub
www.americanbankingnews.com - February 18 at 3:32 PM
Arrowhead Pharmaceuticals Corp (ARWR) Confirms Orphan Drug Status for ARO-AATArrowhead Pharmaceuticals Corp (ARWR) Confirms Orphan Drug Status for ARO-AAT
www.streetinsider.com - February 16 at 5:13 PM
Arrowhead Pharmaceuticals Corp (ARWR) Says it Was Cleared to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis BArrowhead Pharmaceuticals Corp (ARWR) Says it Was Cleared to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
www.streetinsider.com - February 15 at 5:16 PM
Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis BArrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
finance.yahoo.com - February 15 at 5:16 PM
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AATArrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT
finance.yahoo.com - February 15 at 5:16 PM
Brokers Issue Forecasts for Arrowhead Pharmaceuticals Incs FY2018 Earnings (ARWR)Brokers Issue Forecasts for Arrowhead Pharmaceuticals Inc's FY2018 Earnings (ARWR)
www.americanbankingnews.com - February 14 at 11:38 AM
Q2 2018 EPS Estimates for Arrowhead Pharmaceuticals Inc (ARWR) Lifted by AnalystQ2 2018 EPS Estimates for Arrowhead Pharmaceuticals Inc (ARWR) Lifted by Analyst
www.americanbankingnews.com - February 14 at 8:20 AM
William Blair Analysts Raise Earnings Estimates for Arrowhead Pharmaceuticals Inc (ARWR)William Blair Analysts Raise Earnings Estimates for Arrowhead Pharmaceuticals Inc (ARWR)
www.americanbankingnews.com - February 14 at 8:20 AM
Cantor Fitzgerald Analysts Give Arrowhead Pharmaceuticals (ARWR) a $5.00 Price TargetCantor Fitzgerald Analysts Give Arrowhead Pharmaceuticals (ARWR) a $5.00 Price Target
www.americanbankingnews.com - February 12 at 11:18 PM
Arrowhead Pharmaceuticals (ARWR) PT Raised to $4.00 at B. RileyArrowhead Pharmaceuticals (ARWR) PT Raised to $4.00 at B. Riley
www.americanbankingnews.com - February 12 at 11:50 AM
Arrowhead Pharmaceuticals (ARWR) CEO Christopher Anzalone on Q1 2018 Results - Earnings Call Transcript - Seeking AlphaArrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Q1 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 10 at 3:31 PM
Arrowhead Pharmaceuticals (ARWR) Releases Quarterly  Earnings Results, Misses Expectations By $0.04 EPSArrowhead Pharmaceuticals (ARWR) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - February 10 at 10:10 AM
Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter ResultsArrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results
finance.yahoo.com - February 10 at 7:08 AM
Arrowhead Pharmaceuticals Inc (ARWR) Given Consensus Recommendation of "Buy" by AnalystsArrowhead Pharmaceuticals Inc (ARWR) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 10 at 3:24 AM
Arrowhead Pharmaceuticals, Inc. to Host Earnings CallArrowhead Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - February 9 at 3:35 PM
Earnings Scheduled For February 9, 2018 - BenzingaEarnings Scheduled For February 9, 2018 - Benzinga
www.benzinga.com - February 9 at 7:07 AM
Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter ResultsArrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results
finance.yahoo.com - February 3 at 6:58 AM
This Mornings Technical Outlook on Biotech Stocks -- Arena Pharma, Arrowhead Pharma, Axovant Sciences, and BiogenThis Morning's Technical Outlook on Biotech Stocks -- Arena Pharma, Arrowhead Pharma, Axovant Sciences, and Biogen
www.bizjournals.com - January 31 at 7:06 AM
Arrowhead Pharmaceuticals (ARWR) Set to Announce Earnings on MondayArrowhead Pharmaceuticals (ARWR) Set to Announce Earnings on Monday
www.americanbankingnews.com - January 29 at 4:32 AM
Arrowhead Pharmaceuticals Inc (ARWR) Short Interest UpdateArrowhead Pharmaceuticals Inc (ARWR) Short Interest Update
www.americanbankingnews.com - January 28 at 1:26 AM
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 MillionArrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million
finance.yahoo.com - January 23 at 1:10 PM
Arrowhead Pharmaceuticals (ARWR) Neutral Rating Reaffirmed at Chardan CapitalArrowhead Pharmaceuticals' (ARWR) Neutral Rating Reaffirmed at Chardan Capital
www.americanbankingnews.com - January 20 at 6:30 AM
Arrowhead Pharmaceuticals Corp (ARWR) Prices 10M Common Stock Offering at $5.25/Share - StreetInsider.comArrowhead Pharmaceuticals Corp (ARWR) Prices 10M Common Stock Offering at $5.25/Share - StreetInsider.com
www.streetinsider.com - January 19 at 8:04 AM
Arrowhead Pharmaceuticals Corp (ARWR) Prices 10M Common Stock Offering at $5.25/ShareArrowhead Pharmaceuticals Corp (ARWR) Prices 10M Common Stock Offering at $5.25/Share
www.streetinsider.com - January 18 at 3:21 PM
Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common StockArrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
finance.yahoo.com - January 18 at 3:21 PM
After-Hours Movers 01/17: (ESIO) (PTC) (AES) Higher; (ARWR) (PRTK) (IIPR) Lower (more...) - StreetInsider.comAfter-Hours Movers 01/17: (ESIO) (PTC) (AES) Higher; (ARWR) (PRTK) (IIPR) Lower (more...) - StreetInsider.com
www.streetinsider.com - January 18 at 7:21 AM
Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock - Business Wire (press release)Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock - Business Wire (press release)
www.businesswire.com - January 18 at 7:21 AM
Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common StockArrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock
finance.yahoo.com - January 18 at 7:21 AM
38 Biggest Movers From Friday - Benzinga38 Biggest Movers From Friday - Benzinga
www.benzinga.com - January 16 at 6:52 AM
Arrowhead Pharmaceuticals Inc (ARWR) Given Average Recommendation of "Hold" by BrokeragesArrowhead Pharmaceuticals Inc (ARWR) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 16 at 5:56 AM
Here's Why Arrowhead Pharmaceuticals Inc. Is Up TodayHere's Why Arrowhead Pharmaceuticals Inc. Is Up Today
finance.yahoo.com - January 12 at 6:40 AM
Arrowhead Pharmaceuticals: 50% Further Upside Even After Huge Run - Seeking AlphaArrowhead Pharmaceuticals: 50% Further Upside Even After Huge Run - Seeking Alpha
seekingalpha.com - January 9 at 7:17 AM
Arrowhead Pharmaceuticals (ARWR) Coverage Initiated at B. RileyArrowhead Pharmaceuticals (ARWR) Coverage Initiated at B. Riley
www.americanbankingnews.com - January 5 at 8:54 AM
Insider Selling: Arrowhead Pharmaceuticals Inc (ARWR) COO Sells 20,000 Shares of StockInsider Selling: Arrowhead Pharmaceuticals Inc (ARWR) COO Sells 20,000 Shares of Stock
www.americanbankingnews.com - January 3 at 9:52 PM
Arrowhead Pharmaceuticals Inc (ARWR) Short Interest Down 35.2% in DecemberArrowhead Pharmaceuticals Inc (ARWR) Short Interest Down 35.2% in December
www.americanbankingnews.com - December 30 at 3:11 AM
Arrowhead Pharmaceuticals (ARWR) Rating Increased to Buy at BidaskClubArrowhead Pharmaceuticals (ARWR) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - December 28 at 8:42 PM
Arrowhead Pharmaceuticals Corp (ARWR) Appoints William Waddill to Board of DirectorsArrowhead Pharmaceuticals Corp (ARWR) Appoints William Waddill to Board of Directors
www.streetinsider.com - December 27 at 8:12 PM
Arrowhead Pharmaceuticals Appoints William Waddill to Board of DirectorsArrowhead Pharmaceuticals Appoints William Waddill to Board of Directors
finance.yahoo.com - December 27 at 8:12 PM
Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q4, 2017 By the Numbers : December 26, 2017Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q4, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 1:23 PM
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : December 25, 2017ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : December 25, 2017
finance.yahoo.com - December 25 at 3:54 PM
What Caused Arrowhead Pharmaceuticals to Skyrocket 10.5% Today - Motley FoolWhat Caused Arrowhead Pharmaceuticals to Skyrocket 10.5% Today - Motley Fool
www.fool.com - December 24 at 3:26 PM
Arrowhead Pharmaceuticals Corp (ARWR) Files for Clearance to Start Phase 1/2 Study of ARO-HBV - StreetInsider.comArrowhead Pharmaceuticals Corp (ARWR) Files for Clearance to Start Phase 1/2 Study of ARO-HBV - StreetInsider.com
www.streetinsider.com - December 23 at 1:33 AM
Arrowhead Pharmaceuticals Corp (ARWR) Announces Filing of Regulatory Clearance to Begin Phase 1 Study of ARO ... - StreetInsider.comArrowhead Pharmaceuticals Corp (ARWR) Announces Filing of Regulatory Clearance to Begin Phase 1 Study of ARO ... - StreetInsider.com
www.streetinsider.com - December 22 at 6:41 AM
Arrowhead Pharmaceuticals Inc (ARWR) Receives Consensus Recommendation of "Hold" from AnalystsArrowhead Pharmaceuticals Inc (ARWR) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 22 at 6:14 AM
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-AATArrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-AAT
finance.yahoo.com - December 20 at 3:19 PM
FY2018 EPS Estimates for Arrowhead Pharmaceuticals Inc Lifted by Analyst (ARWR)FY2018 EPS Estimates for Arrowhead Pharmaceuticals Inc Lifted by Analyst (ARWR)
www.americanbankingnews.com - December 18 at 3:10 PM

SEC Filings

Arrowhead Pharmaceuticals (NASDAQ:ARWR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Arrowhead Pharmaceuticals (NASDAQ ARWR) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.